

SHCP APC Summary

Date: January 2025

Link to the previous SHCP APC minutes are available [HERE](#)

SHCP APC item	Summary of decision
Budesonide 4mg suppositories - new medicine application	Approved with a GREEN (non-Specialist drug) formulary coding first line for the management of proctitis in ulcerative colitis. Prednisolone suppositories to be second line option for the management of proctitis in ulcerative colitis.
Trixeo Aerosphere® (formoterol fumarate/glycopyrronium/budesonide 5/7.2/160 µg/dose) pressurised metered dose inhaler - new medicine application	Approved with a GREEN (non-Specialist drug) formulary coding.
SHCP APC item	Virtually approved
Lithium Shared Care Protocol (SCP) , for patients within adult services. All new patients to be initiated onto this new SCP.	Approved 08.11.2024 Shared care - Sussex Health & Care (ics.nhs.uk)
DOAC Selection pathway and FAQ document.	Approved 08.11.2024 Atrial fibrillation DOAC pathway and FAQ - NHS Sussex
Extension of cohort for FreeStyle Libre 2+	Approved 18.11.2024 To widen access to FSL 2 Plus to align with <u>current</u> access to FreeStyle Libre 2 in Sussex. Available to view within the 'Prescribing News' section Free Style Libre (FSL) 2 Plus Update - NHS Sussex
Pangrol (Pancreatic Enzyme Replacement Therapy PERT) - request for temporary addition to the formulary	Approved 03.01.2025 PERT shortage information and local actions Available to view https://int.sussex.ics.nhs.uk/clinical_documents/shortage-of-pancreatic-enzyme-replacement-therapy-pert-nhs-sussex-response/
Patiromer (Veltassa®) and Sodium zirconium cyclosilicate (Lokelma®) Information Sheets	Approved updated Information Sheets for Patiromer (Veltassa®) and Sodium zirconium cyclosilicate (Lokelma®) 15.01.2025 Available to download Shared care - Sussex Health & Care (ics.nhs.uk)

(updated)	
Eakin wound pouches - new medicine application	Approved with PURPLE (specialist recommended) formulary coding for use in heavily exuding wounds in community setting.
Items agreed for prescribing to prevent or manage refeeding syndrome in adults	Approved 15.01.2025 Available to download int.sussex.ics.nhs.uk/clinical_documents/refeeding-syndrome-items-agreed-for-prescribing-to-prevent-or-manage-refeeding-syndrome/
Sussex specialist infant formula prescribing guidance includes three separate guidelines for specialist infant formula:	
<ul style="list-style-type: none"> • Sussex guidance for prescribing specialist Infant formula for cow's milk allergy (updated) 	Approved 15.01.2025 Available to download int.sussex.ics.nhs.uk/clinical_documents/infant-feeding-guidance-for-prescribing-specialist-infant-formula-for-cows-milk-allergy/
<ul style="list-style-type: none"> • Sussex guidance for prescribing high energy formula for faltering growth, gastrointestinal (GI) tolerance, and pre-term nutritional products (updated) 	Approved 15.01.2025 Available to download int.sussex.ics.nhs.uk/clinical_documents/infant-feeding-guidance-for-prescribing-high-energy-formula-for-faltering-growth-and-pre-term-formula/
<ul style="list-style-type: none"> • Sussex guidance for specialist infant formulary and thickening powder available to purchase OTC (over the counter) (updated) 	Approved 15.01.2025 Available to download int.sussex.ics.nhs.uk/clinical_documents/infant-feeding-guidance-for-specialist-infant-formula-and-thickening-powder-available-to-purchase-otc/
NICE Technology Appraisals	
NICE TA1012 Avapritinib for treating advanced systemic mastocytosis	Approved RED formulary coding
NICE TA1014 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer	Approved RED formulary coding
NICE TA1015 Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	Approved RED formulary coding
NICE TA1016 Elafibranor for previously treated primary biliary cholangitis	Approved RED formulary coding
NICE TA1017 Pembrolizumab with chemotherapy before surgery (neoadjuvant) then	Approved RED formulary coding

alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	
NICE TA1018 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	Approved RED formulary coding
NICE TA1019 Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over	Approved RED formulary coding
NICE TA1020 Eplontersen for treating hereditary transthyretin-related amyloidosis	Approved RED formulary coding
NICE TA1021 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer	Approved RED formulary coding
NICE TA1022 Bevacizumab gamma for treating wet age-related macular degeneration	Approved RED formulary coding
NICE TA1023 Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	Approved RED formulary coding
NICE TA1025 Ublituximab for treating relapsing multiple sclerosis	Approved RED formulary coding

Discontinuations

Discontinued item	Date discontinued
Calcium 500mg effervescent tablets	Sept 2024
Macrogol compound oral liquid NPF sugar free	Sept 2024
Novo Nordisk Victoza (liraglutide) 6mg/mL pre-filled injection	Oct 2024
Ketoprofen MR 100mg and 200mg Capsules	Oct 2024
Trandate 400mg tablets (RPH Pharmaceuticals AB) (Labetalol)	Oct 2024
NovoRapid (insulin aspart) FlexTouch 100units/ml solution for injection 3ml pre-filled pens	Oct 2024

Duloxetine (Cymbalta) 20mg, 30mg, 40mg and 60mg capsules	Dec 2024
Fusidate (Fucidin) 250mg tablets	Jan 2025
Insulatard Isophane	March 2025
NovoRapid Flexpen	March 2025
Levemir Penfill	December 2026
Levemir Flexpen	December 2026

Formulary status definitions Drug Status Key	
<ul style="list-style-type: none"> • Green-Non-Specialist Drugs • Purple-Specialist recommendation (or initiation where noted) • Amber-Specialist Initiation WITH Shared Care Guidelines 	<ul style="list-style-type: none"> • Red-Specialist ONLY Drugs • Mixed Status - See individual drug entries for more details